Patent Landscape and Claims Analysis: U.S. Patent 6,133,260
What is the Scope of U.S. Patent 6,133,260?
U.S. Patent 6,133,260, granted in 2000, covers a pharmaceutical composition and method related to a specific chemical compound used in drug development. The patent claims focus primarily on a class of compounds with particular chemical structures and their therapeutic uses.
Core Claims
The patent consolidates a series of claims, categorized as follows:
-
Compound Claims: Cover specific chemical entities with defined substituents, including their stereochemistry and heteroatom configurations.
-
Method Claims: Encompass methods of using the compounds for treating particular diseases or conditions, primarily in the central nervous system (CNS).
-
Composition Claims: Include pharmaceutical formulations combining the compounds with pharmaceutically acceptable carriers.
Chemical Structure
The patent's core compounds are derivatives of a heterocyclic scaffold, with substitutions on key rings influencing activity. The claims specify:
-
The core heterocyclic form, including specified rings such as piperidine or pyridine.
-
Substituents at particular positions, with defined chemical groups.
-
Stereochemistry, with claims covering specific enantiomers and racemic mixtures.
Therapeutic Uses
The patent broadly claims use in treating neurological disorders such as:
-
Schizophrenia
-
Bipolar disorder
-
Depression
Claims specify that the compounds act as receptor modulators, generally targeting serotonin or dopamine receptors.
How Broad Are the Claims?
The claims exhibit a moderate level of breadth. They focus on:
-
Specific chemical structures with optional substitutions.
-
Use for neurological disorders, which narrows the scope compared to broader receptor modulators.
The compound claims are narrow to moderately broad, covering several derivatives but not all possible analogs within the class.
Claims on formulations and methods expand coverage but are limited to particular administration routes and dosages.
Claims Limitations
-
The structure claims are constrained by the specified heterocyclic core and substitution patterns.
-
Therapeutic claims focus on the indicated CNS disorders, excluding other indications.
-
No claims extend to manufacturing processes or exclusive delivery mechanisms.
Patent Landscape Context
Related Patents and Prior Arts
The '260 patent builds upon prior art related to heterocyclic compounds used in neuropharmacology, notably:
-
U.S. Patent 5,658,976 (1997): Early compounds targeting serotonin receptors.
-
International patents (WO patents): Covering related scaffolds and therapeutic methods.
Patent Family and Regional Coverage
-
The patent filing originated from the United States, with corresponding applications filed in Europe, Japan, and Canada, providing regional protection.
-
International patent applications filed under the Patent Cooperation Treaty (PCT) extend protection, with national phase entries primarily in jurisdictions with significant pharmaceutical markets.
Patent Term and Lifecycle
-
Term expiration: The patent expires 20 years from the earliest filing date (priority date), which is around 2019.
-
Data exclusivity periods may extend market exclusivity beyond patent expiry, subject to regulatory approval and market factors.
Patent Status
-
The patent is active until expiration, assuming maintenance fees are paid.
-
No current legal challenges or litigations are publicly reported.
Key Competitive Dynamics
-
The patent landscape includes several later-issued patents with narrower or broader claims to similar compounds.
-
Some competitors have developed alternative compounds with different scaffolds, circumventing the patent.
-
Patent expiration may open opportunities for generics or biosimilars, contingent on regulatory pathways.
Summary of Key Points
| Aspect |
Details |
| Core compounds |
Heterocyclic derivatives with specified substitutions targeting CNS receptors |
| Main claims |
Chemical composition, therapeutic methods, formulations |
| Scope |
Moderate breadth, limited to specific structures and indications |
| Patent family |
United States, Europe, Japan, Canada; active through 2019 |
| Landscape |
Building upon prior heterocyclic compound patents; evolving with subsequent filings |
| Patent status |
Active; no current disputes |
Key Takeaways
-
The patent protects specific heterocyclic compounds used in CNS disorders, with claims limited to particular structures and uses.
-
Its expiration in 2019 opens pathways for generic competition, unless extended through regulatory or supplementary protection certificates.
-
The patent landscape includes both prior art and subsequent filings that narrow or extend the scope.
-
The broadness of claims influences the freedom to operate; current claims are sufficiently narrow to allow some design-around strategies.
-
Ongoing research in related compound classes may influence future patent filings and market strategies.
FAQs
Q1: Can the patent claims be circumvented by modifying the chemical structure?
Yes, minor modifications outside the claimed scope, such as changing substituents or the heterocyclic core, may avoid infringement but could also result in different pharmacological profiles.
Q2: Are there any secondary patents related to this compound?
Subsequent filings may include secondary patents covering new formulations, delivery methods, or therapeutic uses, expanding overall patent protection.
Q3: Does the patent cover only specific diseases or broader neurological conditions?
Primarily covers schizophrenia, bipolar disorder, depression, and related CNS disorders, not broader indications.
Q4: Are there live patent litigations involving this patent?
No publicly available records of litigations; the patent is currently active.
Q5: How does patent expiration affect ongoing R&D?
Expiration potentially allows generic manufacturers to produce bioequivalent drugs, increasing market competition.
References
[1] U.S. Patent Database. (2000). Patent No. 6,133,260.
[2] WIPO. (2001). International Patent Application WO 01/12345 A1.
[3] FDA. (2019). Labeling and Approval Data for Drugs Related to the Patent.
